Physician profile
Roy Kellerman
NPI 1568758142
$5,239.34
in general payments reported to CMS, 2019-2025
38 companies · $684 in 2025
The $684 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $562 · 2020: $443 · 2021: $718 · 2022: $557 · 2023: $1,213 · 2024: $1,063 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,960.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $812.84 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.46 | 2021-2025 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $392.88 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $356.84 | 2020-2025 | Airsupra, Wainua |
| Lilly USA, LLC | $321.72 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $321.41 | 2019-2024 | |
| Abbvie INC. | $314.69 | 2021-2025 | |
| Pfizer INC. | $308.46 | 2021-2025 | |
| Abbott Laboratories | $260.26 | 2022-2024 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.40 | 2019-2025 | Xifaxan |
| Astellas Pharma US INC | $134.49 | 2019-2024 | Cresemba |
| Sanofi-Aventis U.S. LLC | $119.26 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $114.06 | 2020-2025 | Austedo Xr |
| Mallinckrodt Hospital Products INC. | $103.82 | 2024-2025 | Terlivaz |
| Janssen Pharmaceuticals, INC | $86.98 | 2020-2024 | Xarelto |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Kellerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.